Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 620 clinical trials
Study of AVB-S6-500 in Combination With Paclitaxel vs Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

This is a Phase 3 study of AVB-S6-500 in combination with paclitaxel (Pac) in patients with platinum resistant recurrent ovarian cancer. This is a randomized, double-blind, placebo-controlled

  • 0 views
  • 28 Aug, 2021
  • 41 locations
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Afuresertib is an AKT inhibitor, a new class of agents under development that may provide physicians with a new clinical option to control platinum resistant ovarian cancer (PROC) progression

  • 10 views
  • 07 Mar, 2021
  • 25 locations
Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT

Advanced small cell ovarian carcinomas are rare and have a very poor prognosis affecting a young population. The objective of this study is to increase the efficacy of the initial chemotherapy

  • 0 views
  • 16 Aug, 2021
  • 10 locations
NUVOLA TRIAL Open-label Multicentre Study

Around 15-25% of ovarian cancer (OC) patients carry germ-line mutation in BRCA1 or BRCA2 genes. Recent evidences showed that OC women with germline BRCA1/2 mutations (gBRCAmut) have an improved

  • 0 views
  • 23 Jan, 2021
  • 1 location
Neoadjuvant Carboplatin in Triple Negative Breast Cancer

Breast cancer is the most frequent neoplasm in women in Brazil and in the world and up to 15% of all cases diagnosed correspond to the triple negative subtype. Triple negative breast cancer affects young women with germline mutations in BRCA 1/2 genes. Giving the lack of target therapies to …

  • 2 views
  • 23 Jan, 2021
  • 1 location
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies

, ovarian cancer and mesothelioma. This feasibility study consists of two parts: (a) a dose escalation phase to select the optimal dose followed by (b) enrollment of additional patients to develop the tumor

  • 0 views
  • 16 Sep, 2021
  • 1 location
Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study

The aim of the study is to explore a prognostic clinical and molecular biomarker profile in a population of BRCA wild-type recurrent high-grade ovarian cancer patients treated with olaparib as

  • 0 views
  • 13 Mar, 2021
  • 1 location
Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

The goal of this clinical research study is to learn if fulvestrant and abemaciclib can help to control low-grade serous ovarian cancer. The safety of this drug combination will also be studied

  • 0 views
  • 23 Jan, 2021
  • 1 location
Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma

Ovarian clear cell carcinoma (OCCC) is one of the rare subtypes of ovarian cancer, yet its prognosis is extremely poor. Previous studies indicates that both bevacizumab and PD-1 inhibitor have

  • 0 views
  • 15 Feb, 2021
  • 1 location
The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers

Women with a BRCA1 mutation face a lifetime risk of breast cancer of approximately 70% and a lifetime risk of ovarian cancer of approximately 40%. A number of potential anti-cancer

mammogram
BRCA1
  • 52 views
  • 08 Nov, 2020
  • 1 location